Core Viewpoint - MBX Biosciences, Inc. has appointed Karen Basbaum as Chief Business Officer, bringing over 20 years of experience in corporate strategy and business development within the biotechnology and pharmaceutical sectors [1][3]. Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][5]. - The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs [5]. Leadership Appointment - Karen Basbaum's extensive background includes leading strategic partnerships and corporate transactions valued at over $10 billion during her tenure at Poseida Therapeutics [3][4]. - Her previous roles include senior positions at DNAtrix, Dauntless Pharmaceuticals, and Elcelyx Therapeutics, contributing to major corporate transactions, including a $7 billion acquisition by Bristol Myers Squibb [4]. Pipeline Development - MBX's pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development, and an obesity portfolio with candidates in various stages of development [5]. - The company is also advancing imapextide (MBX 1416) for post-bariatric hypoglycemia, currently in Phase 2 development [5].
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer